Quantitative Nuclear Medicine Imaging in Oncology. Susan E. Sharp, MD

Similar documents
8/10/2016. PET/CT for Tumor Response. Staging and restaging Early treatment response evaluation Guiding biopsy

Dr Sneha Shah Tata Memorial Hospital, Mumbai.

Integrating FDG PET data for lymphoma management. Michel Meignan, France

PET-imaging: when can it be used to direct lymphoma treatment?

Pediatric Lymphoma Update from the Children s Oncology Group

UK Musculoskeletal Oncology: Something for All Ages. Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky

F NaF PET/CT in the Evaluation of Skeletal Malignancy

Sarajevo (Bosnia Hercegivina) Monday June :30-16:15. PET/CT in Lymphoma

Evaluation of Lung Cancer Response: Current Practice and Advances

Early interim PET (PET2) in Hodgkin Lymphoma patients treated with ABVD. An International Validation Study (IVS).

A Practical Guide to PET adapted Therapy for Hodgkin Lymphoma

Pros and Cons: Interim PET in DLBCL Ulrich Dührsen Department of Hematology University Hospital Essen

The Importance of PET/CT in Human Health. Homer A. Macapinlac, M.D.

8/10/2016. PET/CT Radiomics for Tumor. Anatomic Tumor Response Assessment in CT or MRI. Metabolic Tumor Response Assessment in FDG-PET

Nuclear medicine in oncology. 1. Diagnosis 2. Therapy

Workshop key imaging questions

FDG-PET/CT in the management of lymphomas

FDG PET for therapy response assessment in lymphoma: Beyond Lugano Classification

Lugano classification: Role of PET-CT in lymphoma follow-up

Introduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT

LYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France

Update in Lymphoma Imaging

Hodgkin. The PET World. Sally Barrington

Response Adapted treatment of chl using BV in first line. Massimo Federico University of Modena and Reggio Emilia Italy

Reproducibility of Uptake Estimates in FDG PET: a Monte Carlo study

5 th International Workshop on PET in Lymphoma Menton, September 19-20, 2014 PET adapted trials: The ongoing studies

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW

Targeting and Treating Cancer

SPR 2015 POSTGRADUATE COURSE

PET/MR:Techniques, Indications and Applications

PET/CT for Therapy Assessment in Oncology

SELF-ASSESSMENT MODULE REFERENCE SPR 2018 Oncologic Imaging Course Adrenal Tumors November 10, :00 12:10 p.m.

State of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center

Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010

IAEA RTC. PET/CT and Planning of Radiation Therapy 20/08/2014. Sarajevo (Bosnia & Hercegovina) Tuesday, June :40-12:20 a.

PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD

What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Recommendations for Initial Evaluation, Staging and Response Assessment of Lymphomas

Mediastinal B-cell Lymphomas

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

PET/CT in breast cancer staging

Review Article Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis

Targeting and Treating Cancer

Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL

J Clin Oncol 27: by American Society of Clinical Oncology INTRODUCTION

Staging: Recommendations for bone marrow investigations

Granulocyte-Stimulating Factor-Induced Bone Marrow Reconversion Simulating Neuroblastoma Metastases on MRI: Case Report and Literature Review

children and young people:

FDG-PET/CT in Gynaecologic Cancers

Evaluation of Semi-Quantitative Scoring System for Metaiodobenzylguanidine (mibg) Scans in Patients With Relapsed Neuroblastoma

Musculoskeletal Sarcomas

Lymphoma Read with the experts

Nuclear Medicine: Manuals. Nuclear Medicine. Nuclear imaging. Emission imaging: study types. Bone scintigraphy - technique

Clinical indications for positron emission tomography

Repeatability and reproducibility of 18 F-NaF PET quantitative imaging biomarkers

Role of PET in staging and treatment of lymphomas

On behalf of the Israel Cooperative Lymphoma Group. A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler, I. Ben-Bassat and A.

Cancer will soon become the most common cause of

Practical Application of PET adapted Therapy in Hodgkin Lymphoma

Sally Barrington Martin Hutchings

PET/CT Frequently Asked Questions

METROLOGY TO SUPPORT INNOVATION IN MOLECULAR RADIOTHERAPY. Glenn Flux

SIOP Europe the European Society for Paediatric Oncology European Network for Cancer Research in Children and Adolescents

4th INTERNATIONAL WORKSHOP ON INTERIM-PET IN LYMPHOMA Palais de l Europe, Menton Oct 4-5, 2012

Metabolic volume measurement (physics and methods)

New Visions in PET: Surgical Decision Making and PET/CT

NK/T cell lymphoma Recent advances. Y.L Kwong University Department of Medicine Queen Mary Hospital

Nuclear Medicine in Australia. Shaun Jenkinson

PET/CT and PET/MR of Cardiac Tumors

MRI in lymphoma: where are we in 2016

NEUROBLASTOMA IS the most common extracranial

Assessment of renal cell carcinoma by two PET tracer : dual-time-point C-11 methionine and F-18 fluorodeoxyglucose

Poster Discussion : Hodgkin Lymphoma

Esophageal Cancer. What is the value of performing PET scan routinely for staging of esophageal cancers

Testicular relapse of non-hodgkin Lymphoma noted on FDG-PET

ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London

Role of PET in staging and treatment of lymphomas

Interim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal

FAZA-PET Imaging for Tumour Hypoxia

Spatial clustering of childhood cancers in Switzerland

Theranostics in Nuclear Medicine

Hybrid Imaging SPECT/CT PET/CT PET/MRI. SNMMI Southwest Chapter Aaron C. Jessop, MD

Imaging for Oncologic Response Assessment in Lymphoma

Individualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy)

Radiomics: a new era for tumour management?

Nuclear medicine studies of the digestiv system. Zámbó Katalin Department of Nuclear Medicine

Survival Rates of Childhood Cancer Patients in Osaka, Japan

Role of radiotherapy in the treatment of lymphoma in Lena Specht MD DMSc Professor of Oncology Rigshospitalet, University of Copenhagen Denmark

Case Report Thoracic Primitive Neuroectodermal Tumor: An Unusual Case and Literature Review

Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin s Lymphomas (NHL)

PET/CT in Paediatric Oncology Hybrid Imaging PET/CT & PET MRI

Session II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair

Effective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,

PET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany

Nuclear Medicine in HIV Update with FDG PET

Update on RECIST and Staging of Common Pediatric Tumors Ethan A. Smith, MD

What s new in bone and soft tissue sarcoma Treatment and Guidelines 2012? Rob Grimer

PET for Sarcomas Other Than Gastrointestinal Stromal Tumors

Transcription:

Quantitative Nuclear Medicine Imaging in Oncology Susan E. Sharp, MD

Disclosures None

Objectives Describe scoring systems used in oncologic nuclear medicine imaging Deauville scoring in lymphoma Curie and SIOPEN scoring in neuroblastoma Discuss use of SUV measurements in oncologic FDG PET scans

Scoring Systems

Deauville Scoring in Lymphoma Developed in 2009 by hematologists and nuclear medicine experts Provides a simple and reproducible system for interpretation of interim FDG PET scans good or very good agreement between readers Biggi et al. J Nucl Med 2013;54:683-90.

Deauville Scoring System Five point scale base on visual assessment: 1 = no residual uptake above background 2 = residual uptake < mediastinum 3 = residual uptake > mediastinum, but < liver 4 = residual uptake moderately > liver 5 = residual uptake markedly > liver or new disease sites Biggi et al. J Nucl Med 2013;54:683-90.

Deauville Score = 2 At diagnosis After initial chemotherapy

Deauville Score = 3 At diagnosis After initial chemotherapy

Deauville Score = 5 At diagnosis After initial chemotherapy

Deauville Scoring System Negative: 1 = no residual uptake above background 2 = residual uptake < mediastinum 3 = residual uptake > mediastinum, but < liver Positive: 4 = residual uptake moderately > liver 5 = residual uptake markedly > liver or new disease sites Biggi et al. J Nucl Med 2013;54:683-90.

Interim PET in Hodgkin Lymphoma 3-year Failure Free Survival p < 0.0001 for central review Image from Biggi et al. J Nucl Med 2013;54:683-90.

MIBG Scoring Systems Semi-Quantitative Developed to quantitate disease extent and response improve precision and concordance between readers Curie scoring system used in North America SIOPEN scoring system used in Europe Matthay et al. Br J Cancer. 2010;102(9): 1319-26.

Curie Scoring System Total of 10 compartments: skeleton compartments 1-9 soft tissue compartment 10 Each compartment scored for disease extent on a 3 point scale Total score = sum of compartment scores (maximum score of 30) Image from Matthay et al. Br J Cancer. 2010;102:1319-26.

Curie Scoring System Compartment scores: 0 = no disease sites 1 = one disease site 2 = more than one disease site 3 = diffuse disease involvement Image from Matthay et al. Br J Cancer. 2010;102:1319-26.

SIOPEN Scoring System Total of 12 compartments: skeleton compartments 1-12 no soft tissue compartment Each compartment scored for disease extent on a 6 point scale Total score = sum of compartment scores (maximum score of 72) Image modified from Matthay et al. Br J Cancer. 2010;102:1319-26.

SIOPEN Scoring System Compartment scores: 0 = no disease sites 1 = one disease site 2 = two disease sites 3 = three disease sites 4 = more than three disease sites, but less than 50% involvement 5 = 50-95% involvement 6 = diffuse involvement Image modified from Matthay et al. Br J Cancer. 2010;102:1319-26.

MIBG Scoring Systems Curie and SIOPEN score highly correlated Scores correlate with response/survival in some studies at diagnosis after initial chemotherapy Curie Score > 2 after induction worse event free survival Decarolis et al. J Clin Oncol 2013;31:944-51. Yanik et al. J Nucl Med 2013;54:541-8. Matthay et al. Br J Cancer. 2010;102:1319-26.

SUV Measurements

FDG PET Assessment Qualitative comparison to blood pool, liver, or brain Quantitative measurement of absolute regional radiopharmaceutical concentrations SUVmax percent change in SUVmax metabolic tumor volume tumor-to-non-tumor uptake ratios

SUVmax Widely used and reported SUV measurements are variable and dependent on multiple factors patient preparation scan technique and timing region of interest Studied to determine relationship to histologic response during therapy and survival Wahl et al. J Nucl Med. 2009;50:122S-50S.

Progression Free Survival Based on Tumor Uptake After Neoadjuvant Chemotherapy Ewing Sarcoma Osteosarcoma Images from: Hawkins et al. J Clin Oncol. 2005;23:8828-34. Hawkins et al. Cancer. 2009;115(15):3519-25.

Overall Survival Estimates Based on Primary Tumor Uptake Intensity Rhabdomyosarcoma Image: Baum et al. J Nucl Med. 2011;52:1535-40. Image from Baum et al. J Nucl Med. 2011;52:1535-40.

Conclusions Scoring systems developed to better quantify treatment response and improve concordance between readers Deauville scoring in lymphoma Curie and SIOPEN scoring in neuroblastoma PET allows measurement of absolute regional radiopharmaceutical concentrations parameters such as SUVmax studied to determine ability to predict tumor necrosis and patient survival